Increase In CA125 Research Articles

An increase of serum CA-125 to two times of nadir level strongly predicts the image-identified relapse of serous ovarian cancer

Using 70 U/ml or 35 U/ml as CA125 routine abnormal threshold may result in omissions in the relapse detection of Ovarian cancer (OvCa). This study aimed to clarify the association between a biochemical relapse (only the elevation of CA125) and an image-identified relapse to predict the relapsed lesions better. 162 patients who achieved complete clinical response were enrolled from women diagnosed with stage I-IV serous ovarian, tubal, and peritoneal cancers from January 2013 to June 2019 at our center. The CA125 level of 2 × nadir was defined as the indicator of image-identified relapse (P < 0.001). Compared to CA125 level exceeding 35 U/ml, the 2 × nadir of CA125 improve the sensitivity of image-identified relapse (84.9% vs 67.4%, P < 0.001); the 2 × nadir value can act as an earlier warning relapse signal with a longer median time to image-identified relapse (2.7 vs. 0 months, P < 0.001). Of the relapsed population, there was no difference of CA125 changing trend between the neoadjuvant chemotherapy (NACT) and primary debulking surgery (PDS) group after initial treatment. Compared with 35 U/ml, CA125 reaching 2 × nadir during the follow-up process might be a more sensitive and early relapse signal in patients with serous OvCa. This criterion may help guide patients to be recommended for imaging examination to detect potential relapse in time.

Current Diagnostic Possibilities for the Initial Forms of External Endometriosis

Background. Routine use of ultrasound methods does not always allow detecting endometriosis in the early stages. It is necessary to develop more accurate criteria for the diagnosis of endometriosis in its initial stages of development. Objective: to assess ultrasound and biological markers of endometriosis “small” forms of different localization in infertile women.Material and methods. Ultrasound examination of 208 infertile patients with initial stages of external endometriosis (1–15 points by revised American Fertility Society (rAFS) classificatoon) was performed (main group). The control group consisted of 195 healthy women of childbearing age. To verify the diagnosis, it is suggested to use a panel of biomarkers, including interleukins (IL) 1β and 6, CA125, HE4 as well as the ROMA (Risk of Ovarian Malignancy Algorithm) index in the dynamics of the menstrual cycle.Results. On ultrasound scans, 56 (94.9%) patients had small one- and two-sided ovarian cysts corresponding to endometriosis stage 1–2 (rAFS), and in 3 (5.4%) of them, the ultrasound result was questionable. Detectability during the initial ultrasound examination in the Douglas space was 76.9%, in the rest of cases the ultrasound picture was doubtful. Peritoneal endometriosis was detected only in 5 patients. In the remaining cases (88.9%), additional studies were necessary, including surgical (laparoscopy). The average content of CA125 in the main group on days 3–5 of the menstrual cycle was 42.6 (2.1) U/ml, on days 21–23 – 39.6(2.2) U/ml (p=0.32); in the control group, 5.1 (0.4) and 4.8 (0.7) U/ml, respectively (p = 0.71). The increase in CA125 in the main group was almost 8 times higher than in the control group, however, according to the indicators of HE4 and the ROMA index, statistically significant differences in the groups were not obtained. In the dynamics of the menstrual cycle, the content of ILs in the main group significantly decreased by days 21–23 of the cycle, while the content of CA125 and HE4 remained practically unchanged. Such sharp fluctuations of the considered biomarkers were not detected in the control group. However, even on days 21–23 of the cycle, the average content of ILs and CA125 in women of the main group remained statistically significantly higher than in the control group.Conclusion. In infertile women with dubious ultrasound criteria of external endometriosis, the use of IL1β and IL-6, which stimulate the immune inflammatory response, as well as tumor markers CA125, HE4 and ROMA index allows to differentiate the disease in the initial stages.

A cross-sectional study of 73,390 women without ovarian cancer and the effect of age and benign gynecological diseases on serum CA125 levels.

e17500 Background: As an important tumor marker for follow-up and prognosis of ovarian cancer, CA125 is not suitable as a screening indicator due to its frequent elevation in many physiological or pathological condition, thus women are often puzzled by unaccountably elevated levels of CA125. While we have known that the CA125 level is differed by age and benign gynecological diseases, the specific trend of CA125 level changes is still not clear. We hope that this study will contribute to a more accurate and individual interpretation of CA125 by evaluating the baseline levels of CA125 in healthy women of different ages and analysis the association between benign gynecological diseases and CA125 level. Methods: This was a cross-sectional study enrolled 73390 women without ovarian cancer from January 2016 to December 2021 in three health examination centers. We have assessed the distribution of CA125 levels in different age groups and analyzed the variation trend of CA125 levels by age among women with normal ultrasonic results, as well as performed the correlation analysis between several benign gynecological diseases and CA125 levels. Results: 55422 women with normal ultrasonic results and CA125 level &lt;200U/mL were included in the analysis of variations in CA125 depending on age. We observed CA125 levels were linearly associated with age (R2=0.0503, p&lt;0.0001). Using the group &lt;30 years as a baseline, average CA125 levels decreased by 3.4%, 10.1%, 42.6%, 40.5%, 31.8%, and 20.3% by every 10 years. With the increase of age, the downward trend of CA125 began to reverse at the age of 60, and it showed significantly difference between each adjacent subgroup (p&lt;0.05). 8630 women were selected with abnormal ultrasonic results, we observed that CA125 was lower in women with uterine effusion, higher in endometrial hyperplasia, endometrial polyps, hydrosalpinx, ovarian cyst, adenomyosis and uterine fibroids. Age and all those diseases demonstrated possible associations (p&lt;0.05) with CA125 levels ≥35U/ml in univariable logistic regressions. Multivariable analysis identified that ovarian cyst (p&lt;0.001), adenomyosis (p&lt;0.001) and uterine fibroids (p=0.018) were still significantly associated with abnormal CA125 level. Conclusions: With the increase of age, CA125 level generally showed a downward trend, but there is a slight increase in CA125 after age 60. Ovarian cyst, adenomyosis and uterine fibroids demonstrated significant associations with abnormal CA125 level. [Table: see text]

Clinical significance of CA125 in unresectable pancreatic cancer treated with first-line chemotherapy.

745 Background: Serum CA125 is a potential biomarker for diagnosis of peritoneal metastasis in gastric cancer. However, its significance of pancreatic cancer (PC) has not been investigated. Therefore, we aimed to clarify association between serum CA125 and ascites burden, and its kinetics during first-line chemotherapy for PC. Methods: This multicenter retrospective study comprised PC patients who received FOLFIRINOX or gemcitabine plus nab-paclitaxel in first-line setting between Jan 2014 and Dec 2021. Patient background and treatment outcome was assessed in CA125 elevated and non-elevated group before chemotherapy. The CA125 kinetics after chemotherapy was calculated based on baseline and first measure of CA125. Further, the association between early CA125 change and clinical response during chemotherapy were evaluated based on optimal cut off value calculated receiver operating characteristic (ROC) curve analysis. Results: A total 109 patients from 3 hospitals were assessable. The overall survival (OS) was significantly shorter in elevated group than that in non-elevated group (median, 10.7 vs. 21.3 months, p = 0.0002). The median value of CA125 before chemotherapy was elevated according to ascites burden (Non, 36U/ml; mild, 173U/ml; moderate/severe, 575U/ml; p &lt; 0.0001). CA125 elevation, CA19-9 elevation, poor performance status and poor glasgow prognostic score were independent prognostic factors in multivariate analysis. After chemotherapy, the median first-time measure of CA125 was performed in day 41. Among patients with peritoneal dissemination, the median change of CA125 was correlated with clinical response (CR/PR, -0.55%/day; SD, -0.24%/day; PD, 3.35%/day, p = 0.004). After chemotherapy, first-time measure of CA125 was performed in a median of day 41. According to the ROC curve analysis, the optimal cut-off value of increase in CA125 for progressive disease was 1.56 %/day (specificity 94.1%, sensitivity 80%). The median PFS and OS were 1.4 and 6.6 months in increased group and 3.3 months and 14.0 months in non-increased group, respectively (p = 0.016 and p = 0.028). Conclusions: CA125 is considered a clinically useful marker in unresectable PC treated with first-line chemotherapy because CA125 above the ULN is a poor prognostic factor for OS and an increased CA125 can be an early predictor of progression in patients with peritoneal dissemination.

Meigs syndrome: a case report and literature review

Introduction: Meigs syndrome is defined by the presence of an ovarian benign tumor, ascites, and pleural effusion. The restoration of normal conditions following the removal of the ovarian mass is typical. Although an increase in CA 125 has been reported in association with Meigs syndrome, a level above 1000 IU/mL is unusual, and there is no clear association between patients’ or tumor/cancer characteristics and CA 125 increment to the best of our knowledge. Materials and methods: We conducted a review of Meigs syndrome cases associated with high CA 125 levels and then divided and compared all cases found in the literature and the one described in the text, taking into account the increase of CA 125 = 1000 IU/mL, to identify any possible factor influencing the CA 125 increase. Results: A 55-year-old woman with Meigs syndrome (hydrothorax, ovarian fibroma, and ascites) presented CA 125of 1713 IU/mL. In our review, we found 43 articles that collected 55 cases of Meigs syndrome with an increase inCA 125 of 25% or more than 1000 IU/mL. Considering two groups, divided considering the CA 125 value of 1000IU/mL, we found that the presence of bilateral masses and ascites over 2 L represented independent risk factors for high elevation of CA 125. Conclusion: The presence of bilateral mass and an increase in ascites were associated with an increase in CA125 of 1000 IU/mL, which could be useful in maintaining a benign lesion hypothesis even if the definitive diagnosis could not be made until after surgery, at histological evaluation.

CA-125 monitoring in gynecologic cancer patients with COVID-19: A case series (413)

Objectives: CA-125 has long been utilized as a marker for gynecologic malignancies but can be elevated in many other inflammatory conditions, including lung disease. A retrospective study of tumor markers in non-cancer patients saw a rise in CA-125 values during severe COVID-19 infections. Similarly, a case report published on June 17, 2020, described a significant rise in CA-125 values during an ovarian cancer patient’s COVID-19 infection without evidence of disease progression. Given the potential confounding effect this could have on surveillance and treatment planning, we sought to describe the impact of COVID-19 infections on CA-125 trends in a gynecologic oncology patient population.Methods: We conducted a retrospective chart review of patients treated at a UPMC hospital during the COVID-19 pandemic from March 2020 through July 2021. Patients were included for analysis if they had a confirmed gynecologic malignancy, a COVID-19 infection, and had more than one CA-125 value drawn. The CA-125 values were plotted against the timeline of their COVID-19 infections to assess for trends in CA-125 values during and after infection.Results: There were 78 individuals identified with a COVID-19 infection and a CA-125 drawn following their positive COVID-19 test. Of these 78 patients, 18 had both gynecologic malignancy and more than one CA-125 drawn. Of these 18 patients, only one had an appreciable rise in their CA-125 values at the time of their COVID-19 diagnosis that resolved following their infection and could not be attributed to disease progression. Four patients were diagnosed with cancer at the time of COVID-19 diagnosis and had elevated CA-125 values. One patient passed before receiving treatment, and the other three had CA-125 values that trended down as they received treatment for their cancer. Two patients were noted to have a mild rise in their CA-125 at the time of their COVID-19 infection that continued to rise as they were diagnosed with the progression of their cancer. Most of the 18 patients (n=11, 61.1%) did not show an increase in CA-125 coinciding with their COVID-19 infection. They had either stable or decreasing CA-125 at the time of and following their COVID-19 diagnosis.Conclusions: This case series illustrates that while CA-125 values may increase during acute COVID-19 infection, cancer remains the most likely cause of a CA-125 increase. Clinical suspicion should remain high for a possible change in cancer status.

Evaluation of Tumor Markers Among Patients with Hepatitis C Infection

Tumor markers are biomolecules found in blood, urine and tissue of individuals and, with particularly high concentration in most cancers, therefore, their concentration has diagnostic value. These markers may be used for screening, identification (type and stage), monitoring, and predicting prognosis. Increases in tumor markers are sometimes seen in patients with chronic liver disease without hepatocellular carcinoma (HCC). Objective: To determine the tumor markers, present among patients with Hepatitis C infection. Methods: From April 2021 to March 2022, serum samples from 700 HCV patients who presented to the Department of Pathology at the Pir Syed Abdul Qadir Shah Jeelani Institute of Medical Sciences, Gambat Khairpur Mirs, were used in this descriptive, cross-sectional study. Using the ACCESS-2 system, serum samples were analyzed for the presence of the specified tumor markers. Results: There was a significant increase in CA125 (P = 0.03) and AFP levels (P = 0.03). CA19-9, CEA, and CA15-3 levels in the blood were unremarkable (P &gt; 0.05). It is too early to say if the increase in CA125 or AFP will lead to eventual carcinoma based on this study, but it deserves further exploration using a longitudinal research methodology. Conclusion: CA125 and AF (P were the most common tumor markers found in HCV patients. Given the association of the aforementioned indicators with hepatic cancer, HCV patients with CA125 and AFP levels over normal should be considered high-risk.

Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent Ovarian Cancer.

Ovarian cancer is a disease with significant impact, because more than half of cases exhibit recurrence despite platinum therapy. The choice of drug for cases of recurrence remains controversial, but the current option is pegylated liposomal doxorubicin (PLD). We retrospectively reviewed the use of PLD in patients with ovarian cancer refractory or resistant to platinum-based therapy at our Department. We also examined efficacy, predictive indices of efficacy, and adverse events as well. In this study of PLD monotherapy for 60 platinum-refractory/resistant recurrent ovarian cancers, there was a median progression-free survival (PFS) of 4 months, median overall survival (OS) of 11 months, and the disease control rate (DCR) was 71.7%. The treatment effect can be predicted by the reduction of CA125 level after 2 courses. Patients with an increase and decrease in CA125 after 2 cycles of PLD, respectively, had a median OS of 14.5 (2-60) and 8 (2-51) months and a median PFS of 6 (2-38) months and 3 (0-47) months. PLD is clinically effective and useful because it provides a high DCR and is tolerable to adverse events. These findings can help support the use of PLD and guide physicians in their choice of treatment when encountering such cases.

Serum Level of Ligand Programmed Death-1 in Endometriosis

AIM: In this study, is to evaluate serum level of ligand programmed death-1 (PDL1) in patients with genital endometriosis. MATERIAL AND METHODS: For PDL-1, cancer antigen 125 (CA 125), interleukin (IL)-6, IL-8, tumor necrosis factor (TNF), and vascular endothelial growth factor (VEGF) determination, venous blood was taken 1 h before surgery and/or treatment. All patients were stratified by the presence or absence of endometriosis according to the American Society of Reproductive Medicine’s Revised Classification of Endometriosis of the American Society of Reproductive Medicine. RESULTS: Twenty-one patients with endometriosis participated in the study. The PDL-1 level an experienced group was 55.32 ng/ml (interquartile range [IQR] 34.53–76.20); in the control group was 19.72 ng/ml (IQR 14.72–24.78), which was a statistically significant decrease (p &lt; 0.001). A significant increase in CA125 31.87 (IQR 15.43–36.96) was detected (p &lt; 0.001). In the experimental group, all pro-inflammatory cytokines were elevated (IL-6, IL-8, and TNF, p &lt; 0.013; &lt;0.001; and &lt;0.001) and almost twice increased VEGF 243.44 (IQR 194.56–328.07), (p = 0.016). A noticeable correlation was found between the following indicators PDL-1-CA125, PDL-1-IL-8, and PDL-1-TNF, and a moderate correlation was found between PDL-1 and VEFF (p = 0.006). CONCLUSIONS: The results of the study showed that the levels of PDL-1, CA 125, IL-6, IL-8, TNF, and VEGF were statistically significantly different in the experimental and control groups, and a correlation was also revealed between the levels of PDL-1 and CA125, IL-8 and TNF in patients with genital endometriosis. Therefore, further studies with larger numbers of patients are required.

Clinical features and long-term outcomes after laparoscopic surgery in patients co-existing with ovarian endometrioma and deep infiltrating endometriosis

Objective: To investigate the clinical features and long-term prognosis of patients co-existing with ovarian endometrioma (OMA) and deep infiltrating endometriosis (DIE). Methods: Totally 358 OMA patients were retrospectively analyzed, who had a minimum of 8 years follow-up after laparoscopic cystectomy, which was performed by one professional endometriosis surgery team at Peking Union Medical College Hospital from January 2009 to April 2013. All women were divided into DIE group and non-DIE group, and analysis was performed in preoperative characteristics, surgical findings and postoperative outcomes during follow-up. Results: A total of 358 OMA patients were included, of which 190 patients (53.1%, 190/358) were in the DIE group, while other 168 patients (46.9%, 168/358) in the non-DIE group. The average ages between the two groups were (33.7±5.4), (32.5±5.3) years (P=0.047), the average parity was (0.4±0.6) times vs (0.3±0.5) times (P=0.079). There were significant differences in the proportions of moderate to severe dysmenorrhea [67.4% (128/190) vs 56.5% (95/168)], chronic pelvic pain [24.2% (46/190) vs 7.7% (13/168)], and the increase in CA125 [79.9% (139/190) vs 65.2% (101/168)] between the two groups (all P<0.05). The average operation time in the DIE and non-DIE groups was (75±21) vs (39±36) minutes (P<0.01). There was a significant difference in adenomyosis presence between the two groups [41.6% (79/190) vs 22.0% (37/168); P=0.001]. All patients were followed up for at least 8 years. At the end of the follow-up, though the DIE group was with higher total rate of disease relapse, yet no significant difference was found between the two groups in statistical comparison [21.6% (41/190) vs 16.1% (27/168); P=0.185]. A total of 41 cases in the DIE group recurred, the recurrence rate of pain was 15.8% (30/190), and the recurrence rate of cyst was 8.4% (16/190); 27 cases had recurrence after operation in the non-DIE group, the recurrence rate of pain was 8.9% (15/168), and the recurrence rate of cyst was 10.7% (18/168). There were no significant differences in the pain recurrence rate (P=0.067) and cyst recurrence rate (P=0.460) between the two groups. As for the successfully pregnant patients, live birth rates were 100.0% (65/65) vs 94.4% (68/72) between DIE group and non-DIE groups (P=0.120). Conclusions: Compared with the non-DIE group, OMA patients with concurrent DIE might have severe pain symptoms, higher probability of abnormal CA125 levels and more severe pelvic adhesions. Although there are no significant differences in the total recurrence rate and the recurrence rate of various types between the two groups, the proportion of pain recurrence in the DIE group is higher than that in the non-DIE group. In terms of fertility outcomes, patients in the DIE group are with lower likelihood of pregnancy after surgery during the long-time follow-up. DIE has no significant influence on the fertility outcome.

Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)

ObjectiveTo evaluate the efficacy and safety of regorafenib versus tamoxifen in platinum-sensitive ovarian cancer biological recurrence, defined by CA-125 increase without radiological (RECIST criteria) or symptomatic evidence of progression. Patients and methods116 patients with platinum-sensitive ovarian cancer presenting an isolated increase of CA-125 were planned to be randomized. Regorafenib was administered orally at 160 or 120 mg daily, 3 weeks on/1 week off or tamoxifen at 40 mg daily, until disease progression or development of unacceptable toxicity. The primary endpoint was Progression-Free Survival, assessed by progression according to RECIST 1.1 or death (by any cause). Secondary endpoints included Overall Survival, Best Response and CA-125 response rate. Results68 patients were randomized. Median age was 67 years (range: 30–87). Primary site of cancer was ovarian for most patients (92.6%). Tumors were predominantly serous / (89.7%), high grade (83.6%) and initial FIGO staging was III for 69.6% of the patients. Most (79.4%) patients were included after the first line of platinum-based treatment. After a median follow-up of 32 months, there was no difference of progression-free survival (PFS) between regorafenib and tamoxifen groups (p = 0.72), with median PFS of 5.6 months (CI 90%: 3.84–7.52) for the tamoxifen arm and 4.6 months (CI 90%: 3.65–7.33) for the regorafenib arm. There was also no difference in term of overall survival, best response or CA-125 response, delay to next therapy. Regorafenib presented a less favorable safety profile than tamoxifen, with grade 3/4 events occurring for 90.9% of the patients compared to 54.3% for tamoxifen. The most frequent were cutaneous, digestive, and biological events. Notably, hand-foot syndrome occurred in 36.4% of these patients. ConclusionRegorafenib presented an unfavorable toxicity profile compared to tamoxifen, with no superior efficacy in this population of patients.

Surgical Techniques to Reduce the Diminished Ovarian Reserve Risk of Endometrial Cyst

AIM: The objective of the study was to report the endometriosis case and surgical technique to reduce the diminished ovarian reserve risk. CASE PRESENTATION: A 32-year-old woman was presented with the lower abdominal pain since 1 year ago, intermittent, and got worse during menstruation. The mobile cystic mass was palpable on the abdomen without pain during palpation. Vaginal examination showed mobile and smooth surface cystic mass was palpable, the upper pole was three fingers below the umbilicus, and lower pole was in line with pubic symphysis. Transvaginal ultrasonography (TVUS) showed uterus and right ovary enlargement; and unilocular cyst with homogenous echo pattern. There was a marked increase in CA-125. Based on International Tumor Analysis, the tumor was classified as B1 unilocular cyst and the malignancy risk index was 600. The patient was diagnosed with endometriosis and laparotomy cystectomy was performed. CONCLUSION: Patient was diagnosed with endometrial cyst and laparotomy cystectomy was performed as treatment. Ovarian cystectomy in infertile women was shown to have comparable ovarian reserve (OR), reduced pain symptoms, and increased conception among infertile patients.

Far Infrared Radiation Therapy for Gynecological Cancer-Related Lymphedema Is an Effective and Oncologically Safe Treatment: A Randomized-Controlled Trial.

Background: Gynecological cancer-related lymphedema (GCRL) is a devastating condition that adversely influences function, health, and quality of life. We conducted a randomized-controlled clinical study as well as in vitro experiments to investigate the efficacy and safety of far infrared radiation (FIR) to treat lymphedema in patients having previously undergone surgery for gynecological tumors. Materials and Methods: Seventy-four women with GCRL, cancer free for 5 years or more, were randomly allocated into two treatment groups: standard of care with bandage treatment and treatment with FIR plus bandage. Variations of fluid, circumference of lymphedematous limbs, serum tumor markers (cancer antigen 125 [CA125]), inguinal-pelvic lymph nodes, vagina, lungs, and adverse reactions were assessed after 1 year. In vitro experiments examined the effects on cell viability, proliferation, apoptosis, and the cell cycle of fibroblast, A2780, SKOV-3, HELA, and Ishikawa cells. Results: The FIR+bandage group showed significantly decreased tissue fluid and reduced limb circumference (p < 0.05) in comparison with the control group at 1 year. There was no increase of serum CA125 in both groups, and no recurrence of neoplasia or lymphadenopathy was detected. No adverse reactions were recorded. In addition, no changes were detected after FIR treatment for fibroblast, A2780, SKOV-3, HELA, and Ishikawa cells in cell viability, proliferation, apoptosis, and cell cycle. Conclusion: FIR can be used to treat patients with GCRL following gynecological cancer treatment. Following clinical and experimental studies, we confirm that FIR is an oncologically safe treatment for lymphedema in gynecological tumor patients.

THE ROLE OF SALIVARY AND SERUM CA125 AND ROUTINE BLOOD TESTS IN PATIENTS WITH OVARIAN MALIGNANCIES.

SUMMARYThe use of routine blood tests has recently been shown to be promising in determining disease-free and overall survival in patients with various malignancies, and also in gynecologic malignancies. The aim of this study was to evaluate whether salivary and serum CA125 levels correlate and whether salivary and serum CA125, C-reactive protein and routine blood tests might serve as a prognostic factor in malignant ovarian tumors, and whether they might differentiate between benign and malignant ovarian tumors. A total of 98 women were included (48 with benign ovarian tumors and 50 with malignant ovarian tumors), in whom routine blood tests were made and salivary and serum CA125 levels were determined by use of ELISA. Increase in serum CA125 and amylase decreased overall survival, whereas increase in salivary CA125, potassium levels and hemoglobin increased overall survival. Significant correlation of serum CA125 and C-reactive protein was found in the group with malignant tumors. In conclusion, significant increase in the levels of serum CA125 and amylase correlated with decreased survival, whereas increased salivary CA125, hemoglobin and potassium levels significantly correlated with increased survival.

CA-125 and CCL2 may indicate inflammation in peritoneal dialysis patients.

Introduction:Progressive structural changes in the peritoneal membrane occur over the course of treatment in peritoneal dialysis (PD), resulting in an increase in cytokines such as CCL2 and structural changes in peritoneal membrane triggering an increase in CA-125 in dialysate, which reflects a probable local inflammatory process, with possible loss of mesothelial cells. Thus, the current study aimed to evaluate the association between plasma and CCL2 and CA-125 dialysate levels in patients undergoing PD.Methods:Cross-sectional study was conducted with 41 patients undergoing PD. The assessments of CA-125 and CCL2 levels were performed using a capture ELISA. Correlations were estimated using Spearman's correlation and the investigation of the association between the explanatory variables (CCL2) and response variable (CA-125) was done for crude ratio of arithmetic means and adjusted utilizing generalized linear models.Results:A moderate positive correlation was observed between the levels of CA-125 and CCL2 in the dialysate (rho = 0.696). A statistically significant association was found between the levels in the CCL2 and CA-125 dialysate (RoM=1.31; CI = 1.20-1.43), which remained after adjustment for age (RoM = 1.31; CI=1.19-1.44) and for time in months of PD (RoM=1.34, CI=1.22-1.48).Conclusion:The association of CA-125 levels with CCL2 in the dialysate may indicate that the local inflammatory process leads to temporary or definitive changes in peritoneal membrane. A better understanding of this pathogenesis could contribute to the discovery of new inflammatory biomarkers.

Effect of Body Mass Index on Serum CA125 Level in Females with PCOS

CA125 is a glycoprotein mucins (MUC16) tumor marker, used in screening, ovarian and endometrial malignancies and in monitoring therapy, early recurrences, and prognosis of these cancers. Hormonal induction for ovulation can elevate the risk of ovarian cancers so CA125 may be used for screening in PCOS as an unsafe group and the way of treatment may need to be changed in these patients. Polycystic Ovarian Syndrome (PCOS) is one of the most common hormonal disturbed diseases that can affect females in reproductive life. It has both metabolic and fertility impacts that can be seen in the reproductive period and post-menopausal life. To study the correlation between PCOS and CA125 level in relation to body weight in non-cancerous patients. 60 women were selected with age 18-42-year-old forty of them were diagnosed with PCOS according to Rotterdam criteria. They were divided into two groups according to BMI G1 was more than 25 kg/m2 (overweight and obese) G2 was less than 25 kg/m2 (normal) and the G3 was 20 healthy non-PCOS BMI less than 25 kg/m2. Blood samples were taken in the early follicular phase for assessing luteinizing hormone (LH), follicular stimulating hormone (FSH) and, free testosterone (FT) hormone. Other blood samples were taken at the late follicular phase to measure CA125 levels using Enzyme-Linked Immune Sorbent Assay (ELISA). PCOS G2 were significantly higher in the concentration of CA125 than PCOS G1 (p&lt; 0.05), but there was no significant difference in CA125 level in groups when there is no significant difference in body mass index (BMI) between PCOS G1 and G2. P&gt;0.05. The negative relation between CA125 concentration and weight. The tumor marker CA125 efficacy is decreased in obese women. Furthermore, PCOS not causes an increase in CA125 in the non-cancerous patient.

Dynamic light scattering and fluorescence dual-signal sensing of cancer antigen-125 via recognition of the polymerase chain reaction product with gold nanoparticle probe

Cancer antigen 125 (CA - 125) is an important biomarker for the diagnosis of ovarian cancer. In this paper, oligonucleotide 5′-GACAGGCCCGAAGGAATAGATAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA-3′ (oligo 1) contains an aptamer of CA - 125, and was designed partly complementary to oligonucleotide 5′-CTCTCTCTCCACCTTCTTCTTTGAGCGTTTATTCTTGTCT-3′ (oligo 2). Oligo 1 · oligo 2 was extended with the Klenow fragment (exo−) polymerase for further polymerase chain reaction (PCR) processes in the presence of two primers: deoxyribose nucleoside triphosphate and Taq polymerase. Single-stranded DNA was produced at two sides of the PCR product by introducing a C18 spacer into the two primers, which could hybridize with AuNPs-DNA probes, investigated by dynamic light scattering and fluorescence. The addition of CA - 125 can interrupt the hybridization between oligo 1 and oligo 2, causing the average diameter of AuNPs-DNA probes to decrease with the increase of CA-125 within the range of 5 fg mL−1 – 50 ng mL−1. The linear regression equation of this relationship was D = 430.48–49.60 log10C, with a detection limit of 1.1 fg mL−1. Fluorescein molecules were modified at the end of the forward primer. The fluorescence intensity of the PCR product can be measured simultaneously, with the fluorescence intensity increasing linearly with the logarithm of CA-125 concentration within a linear range from 10 fg mL−1 to 50 ng mL−1, with a detection limit of 1.5 fg mL−1.

Prospective study of the role of HE4 and CA125 in treatment and follow-up in ovarian cancer patients

Introduction: Epithelial Ovarian Cancer, tubal- and peritoneal cancer (EOC) is still the major cause of death in gynecological cancer. The outcome of primary surgery is an important prognostic factor. The primary aim of this study was to study the utility of HE4 and CA125 in monitoring the response of chemotherapy during treatment and in predicting prognosis and recurrence during follow-up. We have also evaluated the role of HE4 as a predictor of the result of surgical intervention. Methods: Seventy-eight patients scheduled for chemotherapy were monitored with serum HE4 and CA125 during treatment and follow-up. In 39 patients samples for tumor markers were also obtained prior to surgical intervention. Results: Both HE4 and CA125 decreased in response to treatment. PFS and OS were strongly dependent on HE4 levels prior to start of chemotherapy with significantly prolonged PFS and OS when HE4 levels were under upper reference limit of 82pmol/L (P=0.018 resp. P&lt;0.001). The levels of HE4 correlated with primary surgical outcome with significantly lower postoperative HE4 in the radically operated group (P&lt;0.001). An increase in HE4 and/or CA125, signals a recurrence 3-6months before diagnosis. Median levels for both HE4 and AC125 before start, during and at the end of treatment were significantly higher for platinum resistant patients (P&lt;0.005). Conclusion: Both tumor markers are valuable in monitoring the response of chemotherapy as well as in predicting recurrence during follow-up. Postoperative HE4 holds promise as an objective marker to evaluate the result of surgery and is highly predictive for future prognosis.

Oncological markers CA-125, CA 19-9 and endometriosis.

The endometrium tissue is functionally androgen related which plays an important role in women's fertility regulation. In addition recent findings show that endometrium related pathology is closely linked to disrupted androgen biosynthesis and associated regulatory functions. These findings also suggest that androgens might play an important role in endometrium related cancer pathology with significant implications for treatment.Based on these findings, we have assessed 50 female outpatients with endometriosis and the clinical investigations were focused on biochemical serum analysis of DHEAS, oncological markers CA-125 and CA 19-9, estradiol, thyreothropic hormone, and prolactin.The results show significant Spearman correlations of CA-125 and CA 19-9 with dehydroepiandrosterone- DHEA-S (R = 0.52 resp. R = 0.49).This result represents 1st reported finding documenting androgen related increase of CA-125 and CA 19-9 levels as significant markers of endometrium pathology and it is possible to assume that these potential biomarkers could have clinical importance with respect to timely diagnosis.

Abstract B19: Genome-wide association study of cancer antigen 125

Abstract CA125 has proven to be the most promising biomarker for ovarian cancer screening. However, results from two large randomized trials comparing screening using CA125 and transvaginal ultrasound (TVU) to usual care have shown no clinically important difference in ovarian cancer mortality. A major limitation of CA125 as an ovarian cancer screening biomarker has been low specificity, which could be due in part to its expression on variety of tissues, including the lung, pancreas, stomach, liver, endometrium, and breast. In addition, CA125 levels vary between individuals based on demographic, reproductive, and lifestyle characteristics. We hypothesize that, independent of ovarian cancer, genetic variation may influence CA125 levels and identification of genetic predictors of CA125 may be used to develop individualized cut-off points, in combination with personal characteristics, to improve the predictive value of CA125 as an ovarian cancer screening biomarker. Furthermore, studies showing that CA125 binds to natural killer cells and monocytes, dampening immune response, suggest that CA125 may contribute to ovarian cancer progression through immune dysregulation. Thus, identifying genetic variants associated with CA125 levels could add another layer of understanding of the biologic role of elevated CA125 in ovarian cancer progression. To test our hypothesis, we evaluated the association between common germline genetic variants across the genome in relation to serum levels of CA125 among 347 women without ovarian cancer recruited as population-based controls in the New England Case Control Study, a population-based study of ovarian cancer that enrolled participants between 1992 and 2008 in eastern Massachusetts and New Hampshire. We used linear regression to identify SNPs associated with CA125 using the Rare variant (RV) test. To account for multiple testing, a p-value threshold of 5x10-8 was used. We adjusted for age and three principal components to account for potential population stratification. While there were no GWAS-significant SNPs, rs12602627 on chromosome 17 was associated with a 75% increase in CA125 per additional variant allele of rs12602627 (p=6.47x10-8). Furthermore, there were two SNPs (rs12602169 and rs73990427) in close proximity that were nearly GWAS significant (p=7.12x10-8 and 8.97x10-8, respectively). rs12602627 explained 8% of the variability of CA125. Monocyte to macrophage differentiation associated (MMD) is the closest gene to rs12602627. MMD encodes a protein expressed in differentiated mature macrophages and is involved in macrophage activation, suggesting it may play an important role in immune response. This is the first GWAS study to assess SNPs directly associated with circulating levels of CA125 in women without ovarian cancer. Validation studies are currently under way. Results from these analyses may provide important insights into genetic determinants of CA125 levels, improved ovarian cancer screening, and better understanding of how CA125 contributes to ovarian cancer pathogenesis and progression. *Coauthors. Citation Format: Naoko Sasamoto, Lai Jiang, Allison F. Vitonis, Raina N. Fichorova, Paul Pharaoh, Daniel W. Cramer, Peter Kraft, Kathryn L. Terry. Genome-wide association study of cancer antigen 125. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr B19.